Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ESMO 2023
Biotech
AstraZeneca places next ADC bet on in-house pipeline
AstraZeneca's David Fredrickson spoke to Fierce Biotech as the FDA accepted an application for the TROP2-directed ADC datopotamab deruxtecan.
James Waldron
Feb 21, 2024 8:00am
At ESMO, oncologists reflect on the global dominance of GLP-1s
Nov 1, 2023 9:52am
Merck hopes internal ADCs reach clinic in 'next couple years'
Oct 26, 2023 11:33am
After Enhertu success, Daiichi and AstraZeneca branch off
Oct 25, 2023 8:00am
ESMO: AstraZeneca's '2.0' cancer pipeline built on bispecifics
Oct 24, 2023 10:36am
Novartis knows what's ahead as peers enter radiopharmaceuticals
Oct 24, 2023 7:00am
